Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Completed · Phase 2

Conditions studied: Human Immunodeficiency Virus (HIV)-1 Infection

In brief

To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and exclusion criteria.

Key facts

Study ID

NCT00380159

Run by

Alexion Pharmaceuticals, Inc.

People needed

4

Starts

2006-09-01

Expected to finish

2009-01-01

Last updated by the study team

2023-08-14

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who have completed 14 days of treatment in Study ACH443-014A and who, in the Investigator's judgment, remain candidates to receive elvucitabine together with background ART.

You may not qualify if…

• Failure to meet inclusion criteria

Where it is running

• Clinical Trial Site — Atlanta, Georgia, United States
• Clinical Trial Site — Cincinnati, Ohio, United States
• Clinical Trial Site — Santo Domingo, Dominican Republic
• Clinical Trial Site — Berlin, Germany
• Clinical Trial Site — Bonn, Germany
• Clinical Trial Site — Cologne, Germany
• Clinical Trial Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.